We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vertex Pharmaceuticals’ cystic fibrosis drug Trikafta (elexacaftor/tezacaftor/ivacaftor) will need a dramatic price cut to be cost effective, the Institute for Clinical and Economic Review (ICER) found in a new analysis.